Hagop Kantarjian: All you need to know about the latest JAK inhibitor to be approved for myelofibrosis
Hagop Kantarjian shared a post on X about a recent paper by Prithviraj Bose published in Blood Journal.
“Momelotinib for the treatment of myelofibrosis”
Author: Prithviraj Bose
“All you need to know about the latest JAK inhibitor to be approved for myelofibrosis in this concise review in Blood Journal by Prithviraj Bose of MD Anderson Cancer Center.”
Source: Hagop Kantarjian/X
Hagop Kantarjian is the professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he also serves as the Samsung Distinguished Leukemia Chair in Cancer Medicine and Associate Vice President for Global Academic Programs.
Dr. Kantarjian’s research focuses on translational-clinical developmental therapeutics in leukemia, spanning over four decades. His contributions include advancements in chronic myeloid leukemia treatment, such as tyrosine kinase inhibitors like imatinib, dasatinib, nilotinib, and bosutinib.
Moreover, he has made discoveries in acute lymphocytic leukemia, myelodysplastic syndrome, and leukemias treatment, resulting in over 20 FDA-approved drugs.